Difference between revisions of "Oxaliplatin (Eloxatin)"
Jump to navigation
Jump to search
m |
m |
||
| Line 5: | Line 5: | ||
*[[Oxaliplatin desensitization protocol]] | *[[Oxaliplatin desensitization protocol]] | ||
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref> | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref> | ||
| + | |||
| + | ==Diseases for which it is established== | ||
| + | *[[Colorectal cancer]] | ||
| + | **[[Colon cancer]] | ||
| + | **[[Rectal cancer]] | ||
| + | *[[Hepatocellular carcinoma]] | ||
==Diseases for which it is used== | ==Diseases for which it is used== | ||
*[[Cholangiocarcinoma]] | *[[Cholangiocarcinoma]] | ||
*[[Chronic lymphocytic leukemia]] | *[[Chronic lymphocytic leukemia]] | ||
| − | |||
| − | |||
| − | |||
*[[Diffuse large B-cell lymphoma]] | *[[Diffuse large B-cell lymphoma]] | ||
*[[Esophageal cancer]] | *[[Esophageal cancer]] | ||
| Line 19: | Line 22: | ||
*[[Gallbladder cancer]] | *[[Gallbladder cancer]] | ||
*[[Gastric cancer]] | *[[Gastric cancer]] | ||
| − | |||
*[[Mantle cell lymphoma]] | *[[Mantle cell lymphoma]] | ||
*[[Marginal zone lymphoma]] | *[[Marginal zone lymphoma]] | ||
Revision as of 02:16, 19 May 2022
General information
Class/mechanism: Platinum analog, alkylating-like, which produces interstrand and intrastrand DNA crosslinks that inhibit DNA replication and transcription, causing non-cell cycle specific cytotoxicity and death.[1][2][3]
Route: IV
Extravasation: irritant (usually), vesicant (rare)
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is established
Diseases for which it is used
- Cholangiocarcinoma
- Chronic lymphocytic leukemia
- Diffuse large B-cell lymphoma
- Esophageal cancer
- Extranodal NK- and T-cell lymphoma, nasal type
- Gallbladder cancer
- Gastric cancer
- Mantle cell lymphoma
- Marginal zone lymphoma
- Nasopharyngeal carcinoma
- Pancreatic cancer
- Testicular cancer
- Transformed lymphoma
Patient drug information
- Oxaliplatin (Eloxatin) package insert PDF pages 15-16[1]
- Oxaliplatin (Eloxatin) patient drug information (Chemocare)[4]
- Oxaliplatin (Eloxatin) patient drug information (UpToDate)[5]
History of changes in FDA indication
Colon cancer
- 11/4/2004: New indication: "used in combination with infusional 5-FU/ LV, is indicated for adjuvant treatment of stage III colon cancer patients who have undergone complete resection of the primary tumor.
Colorectal cancer
- 8/9/2002: Initial accelerated approval in combination with infusional 5-FU/ LV, is indicated for the treatment of patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed during or within 6 months of completion of first line therapy with the combination of bolus 5-FU/ LV and irinotecan.
- 1/9/2004: Converted to regular approval in combination with infusional 5-FU/ LV, is indicated for the treatment of advanced carcinoma of the colon or rectum.
Also known as
- Code names: JM-83, RP-54780, SR-96669
- Brand names: Coxatin, Curaplat, Cure-X, Dacotin, Dacplat, Eloplat, Eloxatin, Eloxatine, Oplatin, OxaLitin, Oxiplat, Oxitan, Oxzucia, Sibatin, Xaloplat, Xylotin, X-Plat, Zildox
References
Categories:
- Drugs
- Intravenous medications
- Platinum agents
- Cholangiocarcinoma medications
- Chronic lymphocytic leukemia medications
- Colon cancer medications
- Colorectal cancer medications
- Diffuse large B-cell lymphoma medications
- Esophageal adenocarcinoma medications
- Esophageal cancer medications
- Esophageal squamous cell carcinoma medications
- Extranodal NK- and T-cell lymphoma, nasal type medications
- Gallbladder cancer medications
- Gastric cancer medications
- Hepatocellular carcinoma medications
- Mantle cell lymphoma medications
- Marginal zone lymphoma medications
- Nasopharyngeal carcinoma medications
- Pancreatic cancer medications
- Rectal cancer medications
- Testicular cancer medications
- Transformed lymphoma medications
- FDA approved in 2002
- WHO Essential Cancer Medicine